These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28864931)

  • 1. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
    Sugihara T; Koizumi M; Koyama M; Terauchi T; Gomi N; Ito Y; Hatake K; Sata N
    Ann Nucl Med; 2017 Dec; 31(10):719-725. PubMed ID: 28864931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer.
    Nakai T; Okuyama C; Kubota T; Yamada K; Ushijima Y; Taniike K; Suzuki T; Nishimura T
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1253-8. PubMed ID: 16133397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
    Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of hormone receptor status in comparison of 18F -FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience.
    Teke F; Teke M; Inal A; Kaplan MA; Kucukoner M; Aksu R; Urakci Z; Tasdemir B; Isikdogan A
    Asian Pac J Cancer Prev; 2015; 16(1):387-91. PubMed ID: 25640386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series.
    Koolen BB; Vegt E; Rutgers EJ; Vogel WV; Stokkel MP; Hoefnagel CA; Fioole-Bruining A; Vrancken Peeters MJ; Valdés Olmos RA
    Ann Nucl Med; 2012 Jan; 26(1):86-91. PubMed ID: 21953212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
    Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
    Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer.
    Al-Muqbel KM; Yaghan RJ
    Medicine (Baltimore); 2016 May; 95(21):e3753. PubMed ID: 27227942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients.
    Ozülker T; Küçüköz Uzun A; Ozülker F; Ozpaçac T
    Nucl Med Commun; 2010 Jun; 31(6):597-603. PubMed ID: 20224457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y; Cullum I; Illidge TM; Ell PJ
    J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
    Portilla-Quattrociocchi H; Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; de Arcocha Torres M; Medina-Quiroz P; del Castillo R; Rubio-Vassallo A; Carril JM
    Rev Esp Med Nucl; 2011; 30(1):2-7. PubMed ID: 21208693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques].
    Withofs N; Collignon J; Rorive A; Jerusalem G; Hustinx R
    Rev Med Liege; 2011; 66(5-6):288-90. PubMed ID: 21826964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
    Sahin E; Zincirkeser S; Akcan AB; Elboga U
    J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET.
    Huyge V; Garcia C; Vanderstappen A; Alexiou J; Gil T; Flamen P
    Clin Nucl Med; 2009 Jul; 34(7):417-20. PubMed ID: 19542943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy.
    Hansen JA; Naghavi-Behzad M; Gerke O; Baun C; Falch K; Duvnjak S; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
    PLoS One; 2021; 16(11):e0260066. PubMed ID: 34793550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract.
    Kim MR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2008 Feb; 44(2):148-52. PubMed ID: 17350879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy.
    Choi YJ; Hwang HS; Kim HJ; Jeong YH; Cho A; Lee JH; Yun M; Lee JD; Kang WJ
    Ann Nucl Med; 2014 May; 28(4):304-13. PubMed ID: 24481823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.
    Dashevsky BZ; Goldman DA; Parsons M; Gönen M; Corben AD; Jochelson MS; Hudis CA; Morrow M; Ulaner GA
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1666-1673. PubMed ID: 25971426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.